Treos Bio, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today named Gábor Illés as its chief financial officer.
Mr. Illés has served as a non-executive investor director of Treos since the company’s inception, and has more than 20 years of corporate finance experience. He joins Treos from BXR Partners LLP, where he was a founding partner.
Mr. Illés, who will be based in Treos’ London headquarters, joins the company as it readies to begin a first-in-man trial of its precision cancer vaccine. In January, Treos announced that the U.S. Food and Drug Administration had accepted its Investigational New Drug (IND) Application for PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC) and has provided authorization to proceed with the phase 1 study in mCRC patients. The vaccine contains six synthetic polypeptides that are precisely selected to induce T cell responses against 12 epitopes from seven cancer testis antigens (CTAs) most frequently expressed in colorectal cancers.
“As Treos turns its attention to raising larger rounds of capital and negotiating partnerships to advance its pipeline, the addition of Gábor as our CFO will bring deep corporate finance experience while maintaining financial discipline to make the most of our resources,” said Dr. Menghis Bairu, executive chairman of Treos. “He will play a critical role in building Treos into a successful immuno-oncology company that addresses the unmet needs of cancer patients.”
“I have long had a strong belief in Treos’ science and the breakthrough potential of its precision cancer vaccines,” said Mr. Illés. “As a dealmaker, this new responsibility represents an unusual opportunity for me to actively contribute to making meaningful improvements in the lives of cancer patients.”